Last reviewed · How we verify
Fluviral influenza vaccine, 2009-2010
Fluviral influenza vaccine, 2009-2010 is a inactivated influenza vaccine Biologic drug developed by Mount Sinai Hospital, Canada. It is currently in Phase 3 development for Seasonal influenza prevention, 2009-2010 season.
Fluviral is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against the 2009-2010 seasonal influenza virus strains.
Fluviral is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against the 2009-2010 seasonal influenza virus strains. Used for Seasonal influenza prevention, 2009-2010 season.
At a glance
| Generic name | Fluviral influenza vaccine, 2009-2010 |
|---|---|
| Sponsor | Mount Sinai Hospital, Canada |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated influenza virus particles or antigens from the predicted circulating strains for that season. Upon administration, it triggers both humoral (antibody) and cellular immune responses, enabling the body to recognize and neutralize the influenza virus if exposed naturally. This provides protection against infection and reduces severity of disease.
Approved indications
- Seasonal influenza prevention, 2009-2010 season
Common side effects
- Injection site soreness or erythema
- Myalgia
- Fever
- Headache
Key clinical trials
- Efficacy Safety Study of Flu Vaccine in Immunodepression Patients (PHASE3)
- Tobacco Use and the Risk of COVID-19 and Adverse Outcomes
- Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years (PHASE1)
- Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years (PHASE3)
- A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines
- Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents (PHASE1)
- FluMist in Egg Allergic Patients (PHASE1, PHASE2)
- A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluviral influenza vaccine, 2009-2010 CI brief — competitive landscape report
- Fluviral influenza vaccine, 2009-2010 updates RSS · CI watch RSS
- Mount Sinai Hospital, Canada portfolio CI
Frequently asked questions about Fluviral influenza vaccine, 2009-2010
What is Fluviral influenza vaccine, 2009-2010?
How does Fluviral influenza vaccine, 2009-2010 work?
What is Fluviral influenza vaccine, 2009-2010 used for?
Who makes Fluviral influenza vaccine, 2009-2010?
What drug class is Fluviral influenza vaccine, 2009-2010 in?
What development phase is Fluviral influenza vaccine, 2009-2010 in?
What are the side effects of Fluviral influenza vaccine, 2009-2010?
Related
- Drug class: All inactivated influenza vaccine drugs
- Manufacturer: Mount Sinai Hospital, Canada — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Seasonal influenza prevention, 2009-2010 season
- Compare: Fluviral influenza vaccine, 2009-2010 vs similar drugs
- Pricing: Fluviral influenza vaccine, 2009-2010 cost, discount & access